Affiliation:
1. Department of Medical Biotechnologies, University of Siena Italy, Policlinico Le Scotte, Viale Bracci 16 53100 Siena, Italy
Abstract
The emergence of drug resistance can seriously compromise HIV type-1 therapy and decrease therapeutic options. Resistance testing is highly recommended to guide treatment decisions and drug activity can be accurately predicted in the clinical setting through genotypic assays. While phenotypic systems are not suitable for monitoring drug resistance in routine laboratory practice, genotyping can misclassify unusual or complex mutational patterns, particularly with recently approved antivirals. In addition, phenotypic assays remain fundamental for characterizing candidate antiretroviral compounds. This review aims to discuss how phenotypic assays contributed to and still play a role in understanding the mechanisms of resistance of both licensed and investigational HIV type-1 inhibitors.
Reference110 articles.
1. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
2. Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies
3. Global burden of transmitted HIV drug resistance and HIV-exposure categories
4. European AIDS Clinical Society (EACS) Treatment Guidelines Update, Version 8.0, (2015). www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services (2016). http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf